Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The...

Inmagene to Host Virtual KOL Event on the Inhibition of the OX40/OX40L Signaling in the Treatment of Atopic Dermatitis and Alopecia Areata SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company developing innovative and differentiated therapies for immunological and...

Inmagene Announces Positive Topline Results of a Multiple Ascending Dose (MAD) Study of IMG-004, a Non-covalent Reversible BTK Inhibitor with Once Daily Dosing Potential IMG-004 was well tolerated across once daily (QD) doses ranging 50 mg to 300 mg for 10 days. Key liver function parameters remained within the normal reference range for all tested doses. No reports...

Inmagene Announces Completion of Enrollment in Phase 2a Trial of IMG-007, a Nondepleting and Half-life Extended Anti-OX40 Monoclonal Antibody, in Patients with Alopecia Areata IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), is being evaluated in adult patients with alopecia areata (AA) and atopic dermatitis (AD).The enrollment of the Phase...

Inmagene Reports Positive Interim Results from Phase 2a Trial of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis...